Abstract:Treating HIV is made difficult by the evolution of antimicrobial resistant mutants of that occurs in the life cycle of this virus. This has led to the evolution of numerous inhibition mechanism that intends to challenges the replication of this virus. One such approach is the application of molecular modelling in drug discovery. In this study the application of computer aided drug design were employed in finding an inhibitor that can contribute in finding a suitable drug candidate. Firstly, the ZINC database was screened using the Lipinski’s rule of five, and compounds having similar biological features were classified and grouped together into a compound library. Secondly, the co-crystallized structure of 1rv7 wild type of HIV-1 protease was used to construct a pharmacophore model that was used to screen further, the ZINC database Ligand stored in the compound library. Thestructure-basedpharmacophore was created by mimicking the three main active features of the co-crystallized structure from the Protein Data Bank, namely, 82 and 84, I50 and I150 residues.Thirdly, a total of twenty-six of the compounds that had less than 0,5 RMSD were identified and selected. Fourthly, based on the best docking ligands, ten of these compounds having high binding affinity were selected. These compounds are ZINC_001456687980 (-8.0), ZINC_001445792073 (-7.8) and ZINC_001461099137 (-7.4), successively. However, ZINC_001461099137 was eliminated based on unfavorable donor-donor interaction. The subsequent compound, ZINC_000015276352 was then placed on the top three leading compounds with a binding affinity of (-6.9). Fifthly, the ADMET property analysis was used on the top ten compounds, and the compounds that satisfied the analysis were, ZINC_001456687980, ZINC_000015276352, ZINC_001359888321 and ZINC_001460445290. The main properties that included the BBB permeation, the gastrointestinal absorption, pan assay interference structure (PAINS), were analyzed. ZINC_001456687980 had two violation (mw >350, XLOGP3>3.5),whiles ZINC_000015276352 had three violations (mw > 350, XLOGP3 > 3.5, rotatable > 7). Lastly, only two top compound underwent molecular dynamics simulations. Molecular dynamics simulation revealed the formation of numerous bond interactions between ZINC_001456687980 and ZINC_000015276352 together with the target protein.

Fragment-Based Screen Against Hiv Protease

Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket

Application of an NMR/crystallography fragment screening platform for the assessment and rapid discovery of new HIV‐CA binding fragments

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro)

A Comparative Insight into Amprenavir Resistance of Mutations V32i, G48v, I50v, I54v, and I84v in Hiv-1 Protease Based on Thermodynamic Integration and Mm-Pbsa Methods

Quantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions

Contrasting the effect of hinge region insertions and non-active site mutations on HIV protease-inhibitor interactions: Insights from altered flap dynamics

Exploring Drug-Resistant Mechanisms of I84V Mutation in HIV-1 Protease Toward Different Inhibitors by Thermodynamics Integration and Solvated Interaction Energy Method

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Insight into binding mechanisms of inhibitors MKP56, MKP73, MKP86, and MKP97 to HIV-1 protease by using molecular dynamics simulation

Some Insights into Mechanism for Binding and Drug Resistance of Wild Type and I50V V82A and I84V Mutations in HIV-1 Protease with GRL-98065 Inhibitor from Molecular Dynamic Simulations.

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Identification of ZINC inhibitors for HIV-1 Protease through Structure-Based Pharmacophore, Virtual Screening, ADMET and Molecular Dynamics Simulation

Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV‐1 Protease

A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution

Evaluating The Potency Of Hiv-1 Protease Drugs To Combat Resistance

Why is Substrate Peptide Binding Unsusceptible to Multidrug-Resistant Mutations in HIV-1 Protease? A Structural and Energetic Analysis

Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein–ligand binding challenge

Screening, Growing, and Validation by Catalog: Using Synthetic Intermediates from Natural Product Libraries to Discover Fragments for an Aspartic Protease Through Crystallography

Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification